Fast FDA Review Expected for Application to Market Siponimod for Secondary Progressive MS
October 8, 2018
Novartis has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s application for marketing approval of oral siponimod for the treatment of adults with secondary progressive MS
. This follows positive results from a phase 3 trial, results of which were previously announced and published
. The company has arranged an expedited review of this application by the FDA, and expects the agency to act on the application in early 2019.
The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.